Core Viewpoint - Semler Scientific, Inc. is facing a class action lawsuit related to securities purchased between March 10, 2021, and April 15, 2025, with a deadline for lead plaintiff motion set for October 28, 2025 [1] Group 1 - Semler disclosed a risk of a potential complaint from the U.S. Department of Justice regarding a civil False Claims Act lawsuit, which could seek damages [3] - The company received an initial civil investigative demand from the DOJ in July 2017 concerning claims for reimbursement related to its QuantaFlo device [3] - Following the announcement of unsuccessful settlement discussions with the DOJ in February 2025, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 on March 3, 2025 [3] Group 2 - The Portnoy Law Firm is representing investors in claims related to corporate wrongdoing and has a history of recovering over $5.5 billion for investors [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Semler Scientific Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - Semler disclosed in its Form 10-K filed on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice (DOJ) in July 2017 regarding reimbursement claims for its QuantaFlo device [2]. - The company has faced multiple requests for information from the DOJ over the years, with significant discussions occurring in February 2025 that did not lead to a settlement [2]. - Following the disclosure of potential legal risks, Semler's stock price fell from $42.92 to $38.89, a decline of $4.03 per share [2]. Next Steps - Investors who purchased Semler shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a law firm recognized for representing investors in various complex litigations across state and federal courts [4].

Core Viewpoint - Semler Scientific, Inc. is facing a class action lawsuit due to alleged securities fraud related to undisclosed investigations by the U.S. Department of Justice regarding the QuantaFlo device reimbursement claims [3][5]. Group 1: Company Background - Semler filed its Form 10-K with the SEC on February 28, 2025, revealing an initial civil investigative demand from the DOJ dating back to July 2017 [3]. - The company has received multiple requests for information from the DOJ over the years, with the latest being in April 2023 [3]. Group 2: Financial Impact - Following the disclosure of the DOJ investigation, Semler's share price dropped by $4.03, approximately 9.39%, from $42.92 to $38.89 between February 28 and March 3, 2025 [3]. - After announcing a settlement agreement of $29.75 million on April 15, 2025, Semler's shares fell by $3.40, or about 9.9%, from $34.40 to $31.00 the following day [4]. Group 3: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Semler securities from March 10, 2021, to April 15, 2025, alleging that the company made false or misleading statements regarding the DOJ investigation [5]. - The lawsuit claims that the company failed to disclose material information about the investigation, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Semler Scientific, Inc. is facing a securities fraud class action lawsuit due to alleged misleading statements regarding a Department of Justice investigation into the company's reimbursement claims related to the QuantaFlo device [3][5]. Group 1: Company Background and Events - On February 28, 2025, Semler disclosed in its Form 10-K that it received a civil investigative demand from the DOJ in July 2017 concerning its reimbursement claims [3]. - Following unsuccessful settlement discussions with the DOJ in February 2025, Semler's share price fell by approximately 9.39%, from $42.92 to $38.89 [3]. - On April 15, 2025, Semler announced a settlement agreement of $29.75 million to resolve all claims, leading to a further decline in share price by about 9.9%, from $34.40 to $31.00 [4]. Group 2: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Semler securities from March 10, 2021, to April 15, 2025, alleging that the company made false or misleading statements regarding the DOJ investigation [5]. - The lawsuit claims that the company failed to disclose material information about the investigation, which resulted in investor damages when the truth was revealed [5].

Core Viewpoint - Semler Scientific Inc. is facing a class action lawsuit due to alleged securities fraud related to undisclosed investigations by the U.S. Department of Justice regarding its QuantaFlo device and reimbursement claims [2][4]. Summary by Sections Company Background - Semler Scientific Inc. (NASDAQ: SMLR) is involved in the development of medical devices, specifically the QuantaFlo device for peripheral artery disease [2]. Legal Developments - On February 28, 2025, Semler disclosed a potential risk of a civil lawsuit from the DOJ regarding its reimbursement claims, which led to a significant drop in its stock price [2][3]. - Following unsuccessful settlement discussions with the DOJ in February 2025, Semler announced on April 15, 2025, an agreement in principle to pay $29.75 million to settle all claims, resulting in another decline in stock price [3]. Stock Performance - After the February 28 announcement, Semler's stock fell by $4.03, or 9.4%, closing at $38.89 on March 3, 2025 [3]. - Following the April 15 announcement, the stock dropped by $3.40, or 9.9%, closing at $31.00 on April 16, 2025 [3]. Allegations in the Lawsuit - The class action lawsuit alleges that Semler made materially false and misleading statements and failed to disclose a DOJ investigation into violations of the False Claims Act, which misled investors about the company's business prospects [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Semler Scientific Inc. for possible violations of federal securities laws and unlawful business practices [1][3]. Company Investigation - Semler Scientific Inc. disclosed in its Form 10-K filed on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice (DOJ) in July 2017 regarding reimbursement claims related to its QuantaFlo device [3]. - The company has faced multiple requests for information from the DOJ over the years, with the most recent being in April 2023 [3]. - Settlement discussions with the DOJ in February 2025 were unsuccessful, and there is a risk of a civil False Claims Act lawsuit being filed against Semler [3]. Stock Performance - Following the news of the DOJ investigation and potential lawsuit, Semler's stock price fell by $4.03, from $42.92 on February 28, 2025, to $38.89 on March 3, 2025 [3].

Core Viewpoint - The Department of Justice is investigating UnitedHealth for allegedly encouraging staff to make specific diagnoses that would lead to higher Medicare payments, particularly under the Medicare Advantage program [1][6]. Investigation Details - The investigation involves inquiries from the Justice Department, FBI, and Health and Human Services regarding patient testing, diagnostic procedures, and the process of sending nurses to patients' homes [2]. - Former employees reported that investigators asked about training related to making diagnoses and the methods used to contact patients for testing [4][8]. Company Response - UnitedHealth maintains that it supports the integrity of its Medicare Advantage business and welcomes regular reviews of its practices [3]. - The company criticized the Wall Street Journal for what it perceives as a biased narrative against Medicare Advantage, claiming reliance on incomplete data [3][4]. Diagnostic Practices - Former doctors indicated that the focus was on coding practices, specifically how diagnosis codes are submitted to Medicare for payments [5]. - Investigators inquired about bonuses for doctors reviewing potential diagnoses suggested by UnitedHealth [7]. Software and Tools - The investigation also looked into the "diagnosis cart" feature of UnitedHealth's software, which suggests potential medical conditions to nurses [11]. - UnitedHealth argues that its diagnostic practices are aimed at early disease detection and plans to implement independent third-party oversight for these practices [8]. Previous Investigations - A separate decade-long effort by the Justice Department to recover alleged Medicare overpayments from UnitedHealth was unsuccessful [10].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Semler Scientific Inc. and its officers or directors [1] Group 1: Legal Investigation - Pomerantz LLP is representing investors of Semler Scientific Inc. in an investigation regarding possible securities fraud [1] - The investigation follows Semler's disclosure of a risk related to a potential complaint from the U.S. Department of Justice regarding the company's reimbursement claims for its QuantaFlo device [3] Group 2: Financial Impact - Following the news of the investigation and the DOJ's involvement, Semler's stock price dropped by $4.03, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Semler Scientific Inc. and its officers or directors [1] Company Summary - Semler Scientific Inc. filed its annual report for 2024 on February 28, 2025, indicating a risk of a civil complaint from the U.S. Department of Justice related to the False Claims Act [3] - The company received an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3] - Settlement discussions with the DOJ in February 2025 were unsuccessful [3] Market Reaction - Following the news of the investigation and potential legal issues, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Disclosure - On February 28, 2025, Semler filed its annual report for 2024, indicating a risk of a complaint from the U.S. Department of Justice (DOJ) related to a civil False Claims Act lawsuit [3]. - Semler disclosed receiving an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3]. - The company participated in unsuccessful settlement discussions with the DOJ in February 2025 [3]. Group 2: Market Reaction - Following the news of the DOJ investigation, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4].